Taysha Gene Therapies (TSHA) Scheduled to Post Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 13th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $3.62 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $1.50 on Monday. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. The firm’s 50 day moving average is $1.98 and its 200-day moving average is $2.39. The firm has a market capitalization of $307.41 million, a price-to-earnings ratio of -7.50 and a beta of 0.44.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TSHA. Canaccord Genuity Group reduced their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Needham & Company LLC decreased their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $6.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.